[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571985":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":25,"responsibleParty":40,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":44,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"European Institute of Oncology","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"patients diagnosed with lung cancer",null,"patients diagnosed with lung cancer (both SCLC and NSCLC)",[13],{"name":14,"affiliation":15,"role":16},"Gabriella Pravettoni","Istituto Europeo di Oncologia","PRINCIPAL_INVESTIGATOR",[18,22],{"name":14,"role":19,"phone":20,"phoneExt":10,"email":21},"CONTACT","+39025489731","gabriella.pravettoni@ieo.it",{"name":23,"role":19,"phone":24,"phoneExt":10,"email":10},"Lorenzo Conti","+390257489731",[26],{"facility":15,"status":27,"city":28,"state":10,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"RECRUITING","Milan","20141","Italy","IT",{"type":33,"coordinates":34},"Point",[35,36],12.59836,42.78235,{"lat":36,"lon":35},[39],{"name":14,"role":19,"phone":24,"phoneExt":10,"email":21},{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100571985","cognitive-screening-in-lung-cancer-patients-100571985",false,"NCT06727370","Cognitive Screening in Lung Cancer Patients","Inclusion Criteria:\n\n* Small-cell and non-small-cell lung cancer (stage I, II, III, IV)\n* Age ≥ 18 years\n* Patients able to speak and read the local language(s) fluently\n* Acceptance and signature of informed consent\n\nExclusion Criteria:\n\n* Age ≥ 70\n* Presence of brain metastases\n* Patients with concomitant neurological or psychiatric disorders.\n* Patients undergoing brain radiotherapy\n* Previous diagnosis of lung cancer","ALL","18 Years","70 Years",{"count":52,"type":53},200,"ESTIMATED","OBSERVATIONAL","This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.",[57,58,59],"Lung Disease","NSCLC (Non-small Cell Lung Cancer)","SCLC",[61,62,63,64],"lung cancer","nsclc","sclc","cognitive","2024-12-06",{"date":67,"type":68},"2024-12-10","ACTUAL",{"date":70,"type":68},"2024-01-10",{"date":72,"type":53},"2025-12-31",{"name":5,"class":6},1]